Literature DB >> 11678898

Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda.

Y Ma1, A L Fracanzani, M Sampietro, M Mattioli, P Cheeseman, R Williams, G Mieli-Vergani, D Vergani, S Fargion.   

Abstract

The enzymes potentially involved in the pathogenesis of sporadic porphyria cutanea tarda (PCT) reside in liver cytosoles and microsomes. PCT is frequently associated with hepatitis C virus (HCV) infection, which is in turn associated with autoimmune manifestations. To investigate whether autoimmune reactions, possibly triggered by HCV, are involved in the pathogenesis of PCT, we measured by immunoblot autoantibodies to human cytosolic and microsomal liver fractions in 82 patients with PCT (77% with HCV infection), 105 with other liver disorders and 40 healthy subjects. Anti-liver cytosolic antibodies were more frequent in PCT patients (38/82, 46%) than in pathological controls (P < 0.05-P < 0.001) or in healthy subjects (3/40, 8%, P < 0.001). Among PCT patients, anticytosolic antibodies were more frequent in HCV positive (36/63, 57%) than in HCV negative (2/19, 11%, P < 0.05) cases. Reactivity to a 40-kDa cytosolic polypeptide was present in 20 PCT patients (19 HCV positive), being more frequent than in all pathological controls (P < 0.01-P < 0.0001). Histological activity index (P = 0.04) and antibodies to HCV (P = 0.027) - but not HCV RNA - were associated independently with anticytosolic antibodies as assessed by multivariate analysis. In contrast, frequency of antiliver microsomal antibodies was similar in PCT patients (24/82, 29%) and pathological controls (8-26%), being higher in the autoimmune hepatitis control group (23/23, 100%, P < 0.0001). In conclusion, anticytosolic antibodies, particularly to a 40-kDa polypeptide, are frequent in PCT and associated with HCV infection and severity of liver damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678898      PMCID: PMC1906169          DOI: 10.1046/j.1365-2249.2001.01645.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue.

Authors:  C DE DUVE; B C PRESSMAN; R GIANETTO; R WATTIAUX; F APPELMANS
Journal:  Biochem J       Date:  1955-08       Impact factor: 3.857

2.  Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection.

Authors:  M J Moran; A Fontanellas; E Brudieux; I Hombrados; V de Ledinghen; P Couzigou; H de Verneuil; R E De Salamanca
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

3.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

Review 5.  Porphyria cutanea tarda.

Authors:  G H Elder
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

6.  High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.

Authors:  M Sampietro; A Piperno; L Lupica; C Arosio; A Vergani; N Corbetta; I Malosio; M Mattioli; A L Fracanzani; M D Cappellini; G Fiorelli; S Fargion
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

7.  Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America.

Authors:  H L Bonkovsky; M Poh-Fitzpatrick; N Pimstone; J Obando; A Di Bisceglie; C Tattrie; K Tortorelli; P LeClair; M G Mercurio; R W Lambrecht
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

8.  Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection.

Authors:  G V Gregorio; P Pensati; R Iorio; A Vegnente; G Mieli-Vergani; D Vergani
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

9.  Porphyria cutanea tarda and hepatitis C virus infection.

Authors:  N Tsukazaki; M Watanabe; H Irifune
Journal:  Br J Dermatol       Date:  1998-06       Impact factor: 9.302

10.  Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort.

Authors:  M Lenzi; S Bellentani; G Saccoccio; P Muratori; F Masutti; L Muratori; F Cassani; F B Bianchi; C Tiribelli
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.